1st Andean Pacific HIV Clinical Forum

Welcome to the Andean Pacific HIV Clinical Forum website!

final_grupoWe would like to thank you for joining us at the Andean Pacific HIV Clinical Forum: Integrase Inhibitors in Santiago, Chile. With 120 participants at the meeting, this event was a great success! We received a lot of positive feedback from you, which we very much appreciate. This will allow us to continue to improve the quality of our meetings.

We deeply enjoyed the discussions and the lectures during this meeting and surely hope you also enjoyed the Networking Dinner on 29 June!

We would like to thank ViiV Healthcare for providing the unrestricted educational grant that made this meeting possible. Also, a big thank you to Mylan for their generous contribution. And of course, thank you to our endorsers ACIN, HealthHIV, and IAPAC for supporting our meeting!

The presentation materials have been made available on Infectious Diseases Online. Simply click on the Presentations button on the right to view any available materials.

We would like to encourage you and your colleagues to plan submission of your upcoming research results to the 2018 meeting. The date and location will be announced in due time.

We hope to see you next year!

Preliminary Program

 Presentations have been posted on InfectiousDiseasesOnline.com

Thursday 29 June

08.00h Registration & Welcome coffee
08.30h Welcome, Introductions and Goals
Carlos Beltrán
Chilean AIDS Cohort (ChiAC), Santiago, Chile
08.45h Resistance Characteristics of Integrase Inhibitors
Charles Boucher
Erasmus Medical Center, Rotterdam, The Netherlands
09.15h Discussion
09.30h Transmitted and Acquired HIV Drug Resistance in Latin America
Luis Enrique Soto Ramirez
Instituto Nacional de Ciencias Médicas y Nutricion Salvador Zubiran, Mexico City, Mexico
10.00h Discussion
10:45h The use of Integrase Inhibitors in Latin America: From guidelines to the Real World
Ernesto Martinez
Universidad del Valle, Cali, Colombia
11.15h PEP after sexual exposures
Mauro Schechter
Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
11.45h Abstract #1:
Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Infected Chilean Patients. Frequency and Evolution between 2013 and 2016.
F. Sidgman
12.00h Abstract #2:
Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed Dose Combination (FDC) compared with Ritonavir boosted Atazanavir (ATV/r) plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in treatment-naïve women with HIV-1 infection (ARIA study): Subgroup analyses
12.15h Clinical Case
Carlos Beltrán
Chilean AIDS Cohort (ChiAC), Santiago, Chile
12.45h Discussion
14.30h Optimizing use of HIV Diagnostic Technologies in Latin America
Ricardo Diaz
NIFESP Laboratorio de Retrovirologia, São Paulo, Brazil
15.00h Discussion
15.15h Abstract #3:
HIV Proviral DNA is an adequate genetic compartment for detection of resistance mutations associated to integrase inhibitors (INIs) therapy in patient with undetected or low viral load.
P. Ferrer
16.00h Reduced Drug Regimens
Pedro Cahn
Fundación Huésped, Buenos Aires, Argentina
16.30h Discussion
16.45h Round Table Discussion: Future of Integrase Inhibitors in Latin America
17.30h End of Meeting
Networking Dinner

Corporate Support

The 1st AndeanPacific HIV Forum meeting: Integrase Inhibitors was generously supported by an unrestricted educational grant from ViiV Healthcare.





The 1st Andean Pacific HIV Clinical Forum was supported by the following endorsers.

ACIN logo 120
Health HIV 120x120


We're not around right now. Please send us an email and we'll get back to you, asap.


©2017 Virology Education

Log in with your credentials


Forgot your details?